Immunohead Biotechnology Co., Ltd, a cell therapy developer based in Suzhou, has reportedly raised close to RMB 200 million (USD 28.89 million) in a Series A+ financing round. The round was led by SDIC Venture Capital, with participation from the Bio-Town Equity Investment Fund. The proceeds will be used to accelerate clinical studies for its IMC001, IMC002, and IMC008 drug candidates.
Company Background and Technology Platform
Founded in 2020, Immunohead Bio is known for its Peri Cruiser technology platform, which enhances the safety and efficacy of chimeric antigen receptor (CAR)-T therapies in solid tumors. The company’s lead drug candidate, IMC001, an autologous EpCAM-CAR-T product, is currently undergoing an investigator-initiated trial (ITT).
Clinical Progress and Future Plans
Immunohead Bio’s VHH antibody-based CLDN18.2-CAR-T therapy, IMC002, has demonstrated good safety and efficacy in pre-clinical studies and ITTs. The company has filed for clinical trial approvals in both China and the US, and has received orphan drug designation (ODD) from the US FDA. Additionally, IMC008, an SNR-CAR-T product, has been filed for an ITT. The funding from the Series A+ round will support the advancement of these candidates through clinical development, positioning Immunohead Bio to make significant strides in the CAR-T therapy space.-Fineline Info & Tech
